Clinical trials
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast clinical trials
Below are recruiting human epidermal growth factor 2 negative carcinoma of breast clinical trials, each written for real people, not researchers. We’re tracking 34 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Scottsdale, ArizonaAges 18 years+ - NCT06616987RecruitingPhase 2
Preventing neutropenia from sacituzumab govitecan in TNBC
This trial tests whether a drug called sacituzumab govitecan can help prevent a low white blood cell count (neutropenia) in people with metastatic triple-negative breast cancer. It is for patients who have already received some chemotherapy but need a new treatment option.
SeoulAges 19 years+ - NCT06361940RecruitingPhase 2
Short-term hormone therapy before breast cancer surgery
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
Milwaukee, WisconsinAges 18 years+ - NCT06700070RecruitingEarly Phase 1
Testing a microdose drug in solid tumors before surgery
This study tests a tiny amount of an experimental drug (PBA-0111) injected directly into tumors that will be surgically removed later. The goal is to see how the drug affects the tumor tissue, which may help guide future treatments for solid tumors like head and neck cancer, certain sarcomas, or triple-negative breast cancer.
Shreveport, LouisianaAges 18 years+ - NCT07647016RecruitingPhase 2
New Drug Combination for Advanced Hormone-Receptor-Positive Breast Cancer
This study tests two drugs together—trastuzumab deruxtecan and ivonescimab—for advanced breast cancer that is hormone-receptor-positive but HER2-negative or HER2-low. These drugs work by targeting cancer cells in different ways and may help slow or shrink tumors in patients whose cancer has progressed after earlier treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07460752RecruitingPhase 2
Alternative injection site for goserelin in breast cancer patients
This trial is testing whether giving the drug goserelin in a different spot on the body works just as well for suppressing ovarian function in premenopausal women with hormone receptor positive breast cancer. You may be a fit if you've already been on goserelin shots in your abdomen for at least 6 months.
Rochester, MinnesotaAges 18–50 - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Denver, ColoradoAges 18 years+ - NCT06533384RecruitingPhase 3
PARP inhibitor or chemo plus immunotherapy after surgery for high-risk TNBC
This trial tests whether adding a PARP inhibitor or capecitabine (chemo) to a PD-1 inhibitor (immunotherapy) after surgery helps prevent triple-negative breast cancer from coming back. It's for people with high-risk disease who have completed initial treatment.
Guangzhou, GuangdongAges 18–70 - NCT06786026RecruitingPhase 2
Drug combo plus chemotherapy for first-line advanced triple-negative breast cancer
This trial tests whether adding an experimental immunotherapy drug (QL1706) with or without bevacizumab to standard chemotherapy can help people with advanced triple-negative breast cancer that hasn't been treated yet. It aims to improve outcomes for patients who have already had earlier treatment but whose cancer has come back or spread.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04669873Recruiting
Partial breast radiation vs whole breast radiation after lumpectomy
This trial studies whether treating only part of the breast with radiation works as well as treating the whole breast in people with early breast cancer after lumpectomy. It may help reduce radiation exposure to healthy tissue, while still controlling the cancer.
São Paulo, São PauloAges 50–90
Hear when a new Human Epidermal Growth Factor 2 Negative Carcinoma of Breast trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for human epidermal growth factor 2 negative carcinoma of breast?
- Yes. Clin2 currently lists 34 recruiting human epidermal growth factor 2 negative carcinoma of breast studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a human epidermal growth factor 2 negative carcinoma of breast trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a human epidermal growth factor 2 negative carcinoma of breast trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- HER2-Negative Breast Carcinoma
- Metastatic Triple-Negative Breast Carcinoma
- Early Stage Triple-Negative Breast Carcinoma
- Metastatic HER2-Negative Breast Carcinoma
- Hormone Receptor Negative Breast Carcinoma
- Unresectable Triple-Negative Breast Carcinoma
- Epidermal Growth Factor Receptor
- Locally Advanced Triple-Negative Breast Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.